🇺🇸 FDA
Pipeline program

Tasimelteon

2022P001873

Phase 1 small_molecule terminated

Quick answer

Tasimelteon for REM Behavior Disorder is a Phase 1 program (small_molecule) at Vanda Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Vanda Pharmaceuticals
Indication
REM Behavior Disorder
Phase
Phase 1
Modality
small_molecule
Status
terminated

Clinical trials